Bayer Cipro XR
This article was originally published in Pharmaceutical Approvals Monthly
FDA approves Bayer's Cipro XR (ciprofloxacin extended-release) Dec. 13 for once-daily treatment of uncomplicated urinary tract infections (UTIs), giving the firm nearly one year to establish the extended-release product before Cipro faces patent expiration in December 2003. The indication was supported by an 891-patient study showing the safety and efficacy of 500 mg Cipro XR to be comparable to conventional 250 mg twice-daily Cipro. An application for complicated UTIs was submitted Oct. 29 (Pharmaceutical Approvals Monthly, Dec. 1, 2002, p. 20). Bayer is highlighting the convenience of the once-daily formulatio
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”